94013-66-8

Upstream product

• 201230-82-2 carbon monoxide 
• 612-15-7 o-methoxystyrene 
• 81616-80-0 (S)-2(2-methoxyphenyl)propionic acid 
• 93-25-4 2-methoxyphenylacetic acid 

Downstream Products

• 188053-29-4 2-(ortho-methoxyphenyl)propan-1-amine 
• 1476076-16-0 6-chloro-N-(2-(2-methoxyphenyl)propyl)pyrimidin-4-amine 
• 1476076-17-1 N-(2-(2-methoxyphenyl)propyl)-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrimidin-4-amine 
• 1476749-06-0 (S)-N-(2-(2-methoxyphenyl)propyl)-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrimidin-4-amine 
• 1476076-15-9 2-(2-(2-methoxyphenyl)propyl)isoindoline-1,3-dione 
• 65921-47-3 1,2-Bis-(o-methoxyphenyl)-propan 

Relevant academic research and scientific papers

Iridium-Catalyzed Domino Hydroformylation/Hydrogenation of Olefins to Alcohols: Synergy of Two Ligands

A novel one-pot iridium-catalyzed domino hydroxymethylation of olefins, which relies on using two different ligands at the same time, is reported. DFT computation reveals different activities for the individual hydroformylation and hydrogenation steps in the presence of mono- and bidentate ligands. Whereas bidentate ligands have higher hydrogenation activity, monodentate ligands show higher hydroformylation activity. Accordingly, a catalyst system is introduced that uses dual ligands in the whole domino process. Control experiments show that the overall selectivity is kinetically controlled. Both computation and experiment explain the function of the two optimized ligands during the domino process.

DNA-PK INHIBITORS

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.